Piperazine derivatives as MAGL inhibitors

US11390610B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Joerg Benz · Rheinfelden (Baden), DE
• Uwe Grether · Weil am Rhein, DE
• Benoit Hornsperger · Altkirch, FR
• Bernd Kuhn · Sursee, CH
• Hans Richter · Weil am Rhein, DE
• Buelent Kocer · Basel, CH
• Fionn O'Hara · Basel, CH
• Martin RITTER · Basel, CH
• Satoshi TSUCHIYA · Shizuoka, JP
• Ludovic COLLIN · Basel, CH
• Simon E. Johnson · Basel, CH
• Charles BELL · Basel, CH

Key dates

• Filing date: Mar 23, 2020
• Grant date: Jul 19, 2022
• Expiry date: Mar 23, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/107
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof,